{"id":"https://openalex.org/W2018471307","doi":"https://doi.org/10.1097/00002826-200603000-00005","title":"Lisuride, a Dopamine Receptor Agonist With 5-HT2B Receptor Antagonist Properties: Absence of Cardiac Valvulopathy Adverse Drug Reaction Reports Supports the Concept of a Crucial Role for 5-HT2B Receptor Agonism in Cardiac Valvular Fibrosis","display_name":"Lisuride, a Dopamine Receptor Agonist With 5-HT2B Receptor Antagonist Properties: Absence of Cardiac Valvulopathy Adverse Drug Reaction Reports Supports the Concept of a Crucial Role for 5-HT2B Receptor Agonism in Cardiac Valvular Fibrosis","alternate_titles":[],"publication_year":2006,"publication_date":"2006-03-01","ids":{"openalex":"https://openalex.org/W2018471307","doi":"https://doi.org/10.1097/00002826-200603000-00005","mag":"2018471307","pmid":"https://pubmed.ncbi.nlm.nih.gov/16614540"},"language":"en","primary_location":{"id":"doi:10.1097/00002826-200603000-00005","doi":"https://doi.org/10.1097/00002826-200603000-00005","is_oa":false,"landing_page_url":"https://doi.org/10.1097/00002826-200603000-00005","pdf_url":null,"source":{"id":"https://openalex.org/S3349026","display_name":"Clinical Neuropharmacology","issn_l":"0362-5664","issn":["0362-5664","1537-162X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","medline","norway-1","poland-40","russia-white-list-3"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Neuropharmacology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2018471307"],"child_works_count":0,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5025219941","display_name":"C. Hofmann","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"C. Hofmann","raw_affiliation_strings":["Global Medical Safety, Schering AG, Berlin, Germany. christoph.hofmann@schering.de","Global Medical Safety, Schering AG, Berlin, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Medical Safety, Schering AG, Berlin, Germany. christoph.hofmann@schering.de","institution_ids":[]},{"raw_affiliation_string":"Global Medical Safety, Schering AG, Berlin, Germany","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046047490","display_name":"U. Penner","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"U. Penner","raw_affiliation_strings":["Global Medical Safety, Schering AG, Berlin, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Medical Safety, Schering AG, Berlin, Germany","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088492491","display_name":"Rainer Dorow","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"R. Dorow","raw_affiliation_strings":["Global Medical Safety, Schering AG, Berlin, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Medical Safety, Schering AG, Berlin, Germany","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108467289","display_name":"Heinz H. Pertz","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I75951250","display_name":"Freie Universit\u00e4t Berlin","ror":"https://ror.org/046ak2485","country_code":"DE","type":"education","lineage":["https://openalex.org/I75951250"]}],"countries":["DE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"H. H. Pertz","raw_affiliation_strings":["Institute of Pharmacy, Free University Berlin, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Institute of Pharmacy, Free University Berlin, Germany","institution_ids":["https://openalex.org/I75951250"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5114914969","display_name":"S. J hnichen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I75951250","display_name":"Freie Universit\u00e4t Berlin","ror":"https://ror.org/046ak2485","country_code":"DE","type":"education","lineage":["https://openalex.org/I75951250"]}],"countries":["DE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"S. J??hnichen","raw_affiliation_strings":["Institute of Pharmacy, Free University Berlin, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Institute of Pharmacy, Free University Berlin, Germany","institution_ids":["https://openalex.org/I75951250"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065573499","display_name":"REINHARD HOROWSKI","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"R. Horowski","raw_affiliation_strings":["NeuroBiotec GmbH, Berlin, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"NeuroBiotec GmbH, Berlin, Germany","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5114914970","display_name":"K. P. Latt","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"K. P. Latt??","raw_affiliation_strings":["NeuroBiotec GmbH, Berlin, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"NeuroBiotec GmbH, Berlin, Germany","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067969299","display_name":"D. Palla","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"D. Palla","raw_affiliation_strings":["NeuroBiotec GmbH, Berlin, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"NeuroBiotec GmbH, Berlin, Germany","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5088082913","display_name":"Bj\u00f6rn Schurad","orcid":"https://orcid.org/0000-0001-6101-5247","observed_orcids":["https://orcid.org/0000-0001-6101-5247"]},"institutions":[{"id":"https://openalex.org/I75951250","display_name":"Freie Universit\u00e4t Berlin","ror":"https://ror.org/046ak2485","country_code":"DE","type":"education","lineage":["https://openalex.org/I75951250"]}],"countries":["DE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"B. Schurad","raw_affiliation_strings":["Institute of Pharmacy, Free University Berlin, Germany","NeuroBiotec GmbH, Berlin, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Institute of Pharmacy, Free University Berlin, Germany","institution_ids":["https://openalex.org/I75951250"]},{"raw_affiliation_string":"NeuroBiotec GmbH, Berlin, Germany","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5025219941","https://openalex.org/A5046047490","https://openalex.org/A5088492491"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":1.4839,"has_fulltext":false,"cited_by_count":115,"citation_normalized_percentile":{"value":0.7826087,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":92,"max":99},"biblio":{"volume":"29","issue":"2","first_page":"80","last_page":"86"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.32249999046325684,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.32249999046325684,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10085","display_name":"Parkinson's Disease Mechanisms and Treatments","score":0.22750000655651093,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10172","display_name":"Cardiac Valve Diseases and Treatments","score":0.06040000170469284,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/lisuride","display_name":"lisuride","score":0.9980000257492065},{"id":"https://openalex.org/keywords/dopamine-agonists","display_name":"dopamine agonists","score":0.8199999928474426},{"id":"https://openalex.org/keywords/cardiac-valvulopathy","display_name":"cardiac valvulopathy","score":0.9520000219345093},{"id":"https://openalex.org/keywords/adverse-drug-reactions","display_name":"adverse drug reactions","score":0.8209999799728394},{"id":"https://openalex.org/keywords/ergolines","display_name":"ergolines","score":0.3930000066757202},{"id":"https://openalex.org/keywords/pergolide","display_name":"pergolide","score":0.8360000252723694},{"id":"https://openalex.org/keywords/cabergoline","display_name":"cabergoline","score":0.8700000047683716},{"id":"https://openalex.org/keywords/bromocriptine","display_name":"bromocriptine","score":0.9950000047683716},{"id":"https://openalex.org/keywords/pleural-fibrosis","display_name":"pleural fibrosis","score":0.8619999885559082},{"id":"https://openalex.org/keywords/pulmonary-fibrosis","display_name":"pulmonary fibrosis","score":0.8059999942779541},{"id":"https://openalex.org/keywords/migraine-prevention","display_name":"migraine prophylaxis","score":0.8560000061988831},{"id":"https://openalex.org/keywords/antiparkinsonian-drugs","display_name":"antiparkinsonian drugs","score":0.8069999814033508}],"concepts":[{"id":"https://openalex.org/C2777095659","wikidata":"https://www.wikidata.org/wiki/Q424446","display_name":"Lisuride","level":5,"score":0.9894561767578125},{"id":"https://openalex.org/C2778717949","wikidata":"https://www.wikidata.org/wiki/Q415752","display_name":"Pergolide","level":5,"score":0.7386314868927002},{"id":"https://openalex.org/C2776856834","wikidata":"https://www.wikidata.org/wiki/Q413581","display_name":"Bromocriptine","level":4,"score":0.6956563591957092},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.6066654920578003},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5341989398002625},{"id":"https://openalex.org/C58732023","wikidata":"https://www.wikidata.org/wiki/Q770260","display_name":"Partial agonist","level":4,"score":0.5293705463409424},{"id":"https://openalex.org/C2778258207","wikidata":"https://www.wikidata.org/wiki/Q600203","display_name":"Dopamine agonist","level":4,"score":0.5003316402435303},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.49473831057548523},{"id":"https://openalex.org/C42219234","wikidata":"https://www.wikidata.org/wiki/Q131130","display_name":"Anesthesia","level":1,"score":0.37027832865715027},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.35797467827796936},{"id":"https://openalex.org/C2779064019","wikidata":"https://www.wikidata.org/wiki/Q66590068","display_name":"Prolactin","level":3,"score":0.20118564367294312},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.19905045628547668},{"id":"https://openalex.org/C71315377","wikidata":"https://www.wikidata.org/wiki/Q11364","display_name":"Hormone","level":2,"score":0.09917524456977844}],"mesh":[{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000978","descriptor_name":"Antiparkinson Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005355","descriptor_name":"Fibrosis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006349","descriptor_name":"Heart Valve Diseases","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":true},{"descriptor_ui":"D006349","descriptor_name":"Heart Valve Diseases","qualifier_ui":"Q000503","qualifier_name":"physiopathology","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008090","descriptor_name":"Lisuride","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012702","descriptor_name":"Serotonin Antagonists","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D014944","descriptor_name":"World Health Organization","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016206","descriptor_name":"Databases, Bibliographic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016208","descriptor_name":"Databases, Factual","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016907","descriptor_name":"Adverse Drug Reaction Reporting Systems","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018491","descriptor_name":"Dopamine Agonists","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D044403","descriptor_name":"Receptor, Serotonin, 5-HT2B","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1097/00002826-200603000-00005","doi":"https://doi.org/10.1097/00002826-200603000-00005","is_oa":false,"landing_page_url":"https://doi.org/10.1097/00002826-200603000-00005","pdf_url":null,"source":{"id":"https://openalex.org/S3349026","display_name":"Clinical Neuropharmacology","issn_l":"0362-5664","issn":["0362-5664","1537-162X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","medline","norway-1","poland-40","russia-white-list-3"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Neuropharmacology","raw_type":"journal-article"},{"id":"pmid:16614540","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/16614540","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical neuropharmacology","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.98580002784729,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":35,"referenced_works":["https://openalex.org/W119330331","https://openalex.org/W1969346649","https://openalex.org/W1973660081","https://openalex.org/W1975959562","https://openalex.org/W1976813386","https://openalex.org/W1990664163","https://openalex.org/W2009589490","https://openalex.org/W2010595984","https://openalex.org/W2011985298","https://openalex.org/W2023108138","https://openalex.org/W2026777477","https://openalex.org/W2028849336","https://openalex.org/W2035555985","https://openalex.org/W2040205334","https://openalex.org/W2045668572","https://openalex.org/W2046191363","https://openalex.org/W2058366693","https://openalex.org/W2063643899","https://openalex.org/W2065941911","https://openalex.org/W2066847148","https://openalex.org/W2070494518","https://openalex.org/W2086990019","https://openalex.org/W2092557965","https://openalex.org/W2092980697","https://openalex.org/W2109014958","https://openalex.org/W2113404778","https://openalex.org/W2124057487","https://openalex.org/W2138904234","https://openalex.org/W2145017337","https://openalex.org/W2163161835","https://openalex.org/W2168954492","https://openalex.org/W2196566018","https://openalex.org/W2368590639","https://openalex.org/W2415645458","https://openalex.org/W4252472226"],"related_works":["https://openalex.org/W2079691047","https://openalex.org/W2075342175","https://openalex.org/W2379123957","https://openalex.org/W2116842672","https://openalex.org/W2128907802","https://openalex.org/W2138904234","https://openalex.org/W1985003601","https://openalex.org/W1996599240","https://openalex.org/W2158646569","https://openalex.org/W121198585"],"abstract_inverted_index":{"OBJECTIVES:":[0],"The":[1,313],"high":[2],"incidence":[3,316],"of":[4,41,73,94,107,116,124,152,168,188,207,221,223,227,286,310,317,320,345,365],"fibrotic":[5,299],"cardiac":[6,110,134,172,190,300,391],"valvulopathies":[7,135,173,392],"reported":[8],"in":[9,38,75,118,199,239,279,302,333,353],"association":[10,167,330],"with":[11,109,171,181,193,242,304,328,356,379,395],"the":[12,32,39,45,50,59,71,125,128,158,280,305,334,354,363,384],"8beta-ergoline":[13],"dopamine":[14],"(DA)":[15],"agonist,":[16,44],"pergolide,":[17],"and":[18,24,35,64,81,97,127,246,298,374],"also":[19],"case":[20,40],"reports":[21,115,253,319],"for":[22,52,61,103,113,342],"cabergoline":[23],"bromocriptine":[25],"have":[26,69,83,214],"made":[27],"it":[28],"necessary":[29],"to":[30,77,139,175,337,350,383],"review":[31,123],"theoretical":[33],"basis":[34],"actual":[36],"findings":[37],"another":[42],"DA":[43,79,376],"8alpha-ergoline":[46],"lisuride":[47,74,108,149,169,194,281,296],"(used":[48],"since":[49,58],"1970s":[51],"migraine":[53],"prophylaxis":[54],"as":[55,57,89,91,393],"well":[56,90],"1980s":[60],"its":[62],"prolactin-lowering":[63],"anti-Parkinson":[65],"activity).":[66],"METHODS:":[67],"We":[68],"reviewed":[70],"pharmacology":[72,126],"relation":[76],"other":[78,98,119,225,243,266,322],"agonists,":[80],"we":[82,213],"performed":[84],"a":[85,92,104,140,185,189,205,217,366],"throughout":[86],"literature":[87,129],"search":[88,93],"our":[95,358],"own":[96],"adverse":[99,282],"drug":[100,142,283],"reaction":[101,284],"databases":[102],"possible":[105],"relationship":[106],"valvulopathy":[111,191],"or":[112,389],"any":[114,200,224,321],"fibrosis":[117,228,323],"locations.":[120],"RESULTS:":[121],"Our":[122],"strongly":[130],"suggests":[131],"that":[132,370],"drug-induced":[133],"are":[136],"always":[137],"related":[138,268],"stimulatory":[141],"effect":[143,309,368],"on":[144,157],"trophic":[145],"5-HT(2B)":[146,164,306],"receptors.":[147],"As":[148],"is":[150,160,348],"devoid":[151],"such":[153],"an":[154,161,166,208,329],"effect,":[155],"but":[156],"contrary":[159],"extremely":[162],"potent":[163],"antagonist,":[165],"therapy":[170,195,355],"seems":[174],"be":[176,325,351],"highly":[177],"unlikely.":[178],"In":[179,262],"agreement":[180,303],"this":[182,311,343],"hypothesis,":[183],"not":[184,361],"single":[186],"report":[187],"associated":[192],"has":[196,292],"been":[197,293],"identified":[198,278],"database":[201,285],"so":[202],"far.Furthermore,":[203],"against":[204],"background":[206],"estimated":[209],"360,000":[210],"patient":[211],"years,":[212],"found":[215,294],"only":[216,264],"very":[218,314],"small":[219],"number":[220],"cases":[222],"form":[226],"(1x":[229,257],"retroperitoneal,":[230,258],"2x":[231,233],"pleural,":[232],"pulmonary,":[234],"1x":[235,273,275],"interstitial":[236],"pulmonary":[237],"changes),":[238],"part":[240],"combined":[241],"risk":[244],"factors":[245],"confounding":[247],"variables.":[248],"This":[249],"closely":[250],"matches":[251],"4":[252],"available":[254],"from":[255],"WHO":[256],"3x":[259],"pleural":[260,271],"fibrosis).":[261],"addition,":[263],"5":[265],"possibly":[267],"conditions":[269],"(3x":[270],"effusion,":[272],"pleuritis,":[274],"pericarditis)":[276],"were":[277],"Schering,":[287],"Berlin.":[288],"CONCLUSIONS:":[289],"No":[290],"link":[291],"between":[295],"use":[297],"valvulopathy,":[301],"receptor":[307,377],"antagonist":[308],"drug.":[312],"low":[315],"spontaneous":[318],"could":[324],"even":[326],"compatible":[327],"by":[331],"chance":[332],"population":[335],"exposed":[336],"lisuride.":[338],"Although":[339],"close":[340],"monitoring":[341],"kind":[344],"side":[346],"effects":[347],"still":[349],"recommended":[352],"lisuride,":[357],"data":[359],"do":[360],"support":[362],"concept":[364],"class":[367],"suggesting":[369],"all":[371],"ergot-derived":[372],"drugs":[373],"especially":[375],"agonists":[378],"some":[380],"chemical":[381],"similarity":[382],"ergot":[385],"structure":[386],"will":[387],"cause":[388],"facilitate":[390],"observed":[394],"pergolide.":[396]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2018471307","counts_by_year":[{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":5},{"year":2022,"cited_by_count":5},{"year":2021,"cited_by_count":4},{"year":2020,"cited_by_count":6},{"year":2019,"cited_by_count":5},{"year":2018,"cited_by_count":3},{"year":2017,"cited_by_count":3},{"year":2016,"cited_by_count":6},{"year":2015,"cited_by_count":9},{"year":2014,"cited_by_count":5},{"year":2013,"cited_by_count":7},{"year":2012,"cited_by_count":11}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-06-24T00:00:00"}
